| NCT06843590 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Idiopathic Hypersomnia | RECRUITING | PHASE2 | 2025-05-22 | 2026-06 | 2026-06 |
| NCT06767683 | A Long-Term Study of ALKS 2680 in Subjects With Narcolepsy and Idiopathic Hypersomnia | RECRUITING | PHASE2, PHASE3 | 2025-01-27 | 2028-06 | 2028-06 |
| NCT06555783 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 2 | ACTIVE_NOT_RECRUITING | PHASE2 | 2024-07-26 | 2025-11 | 2025-11 |
| NCT06358950 | A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201) | COMPLETED | PHASE2 | 2024-03-28 | 2025-07-31 | 2025-06-19 |
| NCT05547100 | Study of the Breast Milk Pharmacokinetics of Olanzapine and Samidorphan | COMPLETED | PHASE1 | 2022-09-14 | 2022-11-19 | 2022-11-19 |
| NCT05303064 | Study to Evaluate Weight Gain as Assessed by Change in BMI Z-score in Pediatric Subjects With Schizophrenia or Bipolar I Disorder | RECRUITING | PHASE3 | 2022-06-30 | 2026-09 | 2026-09 |
| NCT04987229 | Long-term Safety Extension Study of OLZ/SAM in Pediatric Subjects | ENROLLING_BY_INVITATION | PHASE3 | 2021-10-22 | 2027-09 | 2027-09 |
| NCT05019105 | Phase 1 ALKS 1140 in Healthy Adults | TERMINATED | PHASE1 | 2021-10-13 | 2022-08-23 | 2022-08-23 |
| NCT04987658 | Phase 1 Study of OLZ/SAM in Pediatric Subjects With Bipolar I Disorder | COMPLETED | PHASE1 | 2021-07-22 | 2023-08-11 | 2023-08-11 |
| NCT03963973 | A 28 Day Parallel Group Study to Assess the Effects of RDN-929 | TERMINATED | PHASE1 | 2019-05-16 | 2020-01-22 | 2020-01-22 |
| NCT03668314 | Single and Multiple Ascending Dose and Food Effect PK Study in Healthy Adult and Elderly Subjects | COMPLETED | PHASE1 | 2018-10-10 | 2019-04-15 | 2019-04-15 |
| NCT03610048 | A Long Term Study of ALKS 5461 in the Treatment of Refractory Major Depressive Disorder (MDD) | TERMINATED | PHASE3 | 2018-08-09 | 2020-05-01 | 2020-05-01 |
| NCT03577262 | A Non-therapeutic Feasibility Study of the Radioligand [11C]-UCB-J for Imaging Synaptic Density | COMPLETED | EARLY_PHASE1 | 2018-07-23 | 2019-08-02 | 2019-08-02 |
| NCT03345979 | A Study of Aripiprazole Lauroxil or Paliperidone Palmitate for the Treatment of Schizophrenia | COMPLETED | PHASE3 | 2017-11-15 | 2019-03-12 | 2019-03-12 |
| NCT03201757 | Study to Evaluate the Long-term Safety, Tolerability, and Durability of Treatment Effect of ALKS 3831 | COMPLETED | PHASE3 | 2017-06-15 | 2023-09-06 | 2023-09-06 |
| NCT03188185 | A Study of ALKS 5461 for Treatment Refractory Major Depressive Disorder (MDD) | COMPLETED | PHASE3 | 2017-06-12 | 2020-03-05 | 2020-02-26 |
| NCT03187769 | Study to Evaluate the Efficacy of ALKS 3831 on Body Weight in Young Adults Who Have Been Recently Diagnosed With Schizophrenia, Schizophreniform, or Bipolar I Disorder | COMPLETED | PHASE3 | 2017-06-08 | 2022-01-03 | 2021-12-01 |
| NCT02922426 | An Insulin Sensitivity Study in Healthy Subjects | COMPLETED | PHASE1 | 2016-09 | 2017-07-20 | 2017-07-20 |
| NCT02873208 | A Phase 3, Long-term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia | COMPLETED | PHASE3 | 2016-08-07 | 2019-10-17 | 2019-10-17 |
| NCT02804568 | A Phase 1 Safety Study in Adults With Schizophrenia | COMPLETED | PHASE1 | 2016-06 | 2016-08 | 2016-08 |
| NCT02696434 | Evaluating Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Transitioning From Buprenorphine Maintenance Prior to First Dose of VIVITROL | COMPLETED | PHASE3 | 2016-04 | 2017-11-30 | 2017-11 |
| NCT02694328 | A Study of ALKS 3831 in Adults With Schizophrenia (The ENLIGHTEN-2 Study) | COMPLETED | PHASE3 | 2016-03-02 | 2018-11-07 | 2018-11-07 |
| NCT02669758 | A Long-Term Safety and Tolerability Study of ALKS 3831 in Adults With Schizophrenia | COMPLETED | PHASE3 | 2016-01-20 | 2018-06-29 | 2018-06-29 |
| NCT02634320 | A Study of Aripiprazole Lauroxil (Also Known as ARISTADA TM) in Subjects With Schizophrenia | COMPLETED | PHASE4 | 2015-12 | 2017-07-11 | 2017-07-11 |
| NCT02634346 | A Study of ALKS 3831 in Adults With Acute Exacerbation of Schizophrenia (the ENLIGHTEN-1 Study) | COMPLETED | PHASE3 | 2015-12 | 2017-06-07 | 2017-05-25 |
| NCT02636842 | A Study of Aripiprazole Lauroxil in Subjects With Schizophrenia or Schizoaffective Disorder | COMPLETED | PHASE1 | 2015-12 | 2016-06 | 2016-06 |
| NCT02537574 | Naltrexone for Use in Conjunction With Buprenorphine in Adults With Opioid Use Disorder Prior to First Dose of VIVITROLĀ® (Naltrexone for Extended-Release Injectable Suspension) | COMPLETED | PHASE3 | 2015-08 | 2017-01-09 | 2016-10-27 |
| NCT02508506 | Pharmacokinetics and Safety of ALKS 5461 in Subjects With Renal Impairment and Normal Renal Function | COMPLETED | PHASE1 | 2015-07 | 2015-12 | 2015-12 |
| NCT02545439 | A Drug-drug Interaction Study of ALKS 5461 in Healthy Volunteers | COMPLETED | PHASE1 | 2015-07 | 2015-10 | 2015-10 |
| NCT02521857 | A Water Consumption Study of ALKS 5461 in Healthy Volunteers | COMPLETED | PHASE1 | 2015-07 | 2015-09 | 2015-09 |
| NCT02479308 | A Study to Evaluate the Effect of ALKS 5461 on QT Intervals in Healthy Volunteers | COMPLETED | PHASE1 | 2015-06 | 2015-10 | 2015-10 |
| NCT02504463 | A Study of [14c]-Samidorphan (Also Known as ALKS 33) in Healthy, Male Volunteers | COMPLETED | PHASE1 | 2015-06 | 2015-09 | 2015-09 |
| NCT02452801 | Pharmacokinetics and Safety of ALKS 5461 in Healthy Subjects and Subjects With Hepatic Impairment and Normal Hepatic Function | COMPLETED | PHASE1 | 2015-05 | 2015-12 | 2015-12 |
| NCT02413281 | A Study of the Abuse Liability Potential of ALKS 5461 in Healthy, Non-Dependent, Recreational Opioid Users | COMPLETED | PHASE1 | 2015-03 | 2015-09 | 2015-09 |
| NCT02320032 | An Open-Label Study of Aripiprazole Lauroxil in Subjects With Stable Schizophrenia | COMPLETED | PHASE1 | 2014-12 | 2016-04 | 2016-04 |
| NCT02272764 | A Drug-Drug Interaction Study of ALKS 5461 in Healthy Volunteers | COMPLETED | PHASE1 | 2014-10 | 2014-11 | 2014-11 |
| NCT02218021 | A Study of the Abuse Liability Potential of Samidorphan in Healthy, Non-Dependent, Recreational Opioid Users | COMPLETED | PHASE1 | 2014-08 | 2014-11 | 2014-11 |
| NCT02218008 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - FORWARD-5 Study | COMPLETED | PHASE3 | 2014-07 | 2016-10 | 2016-09 |
| NCT02161718 | A Study of ALKS 3831 in Subjects With Schizophrenia and Alcohol Use Disorder | COMPLETED | PHASE2 | 2014-05 | 2017-02-01 | 2017-01-11 |
| NCT02158533 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-4 Study | COMPLETED | PHASE3 | 2014-05 | 2015-12 | 2015-12 |
| NCT02158546 | A Study of ALKS 5461 for the Treatment of Major Depressive Disorder (MDD) - the FORWARD-3 Study | COMPLETED | PHASE3 | 2014-05 | 2015-12 | 2015-12 |
| NCT02141399 | A Long-Term Safety Study of ALKS 5461 | COMPLETED | PHASE3 | 2014-05 | 2017-11-20 | 2017-11-20 |
| NCT02085135 | A Study of Different Titration Schedules of ALKS 5461 in Adults With Major Depressive Disorder (MDD) | COMPLETED | PHASE3 | 2014-02 | 2014-09 | 2014-09 |
| NCT02068105 | A Study of ALKS 5461 in Healthy Volunteers | COMPLETED | PHASE1 | 2014-01 | 2014-03 | 2014-03 |
| NCT01895452 | An Extension of a Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | COMPLETED | PHASE3 | 2013-07 | 2016-06 | 2016-06 |
| NCT01903837 | A Study of ALKS 3831 in Adults With Schizophrenia | COMPLETED | PHASE2 | 2013-06 | 2015-03 | 2014-12 |
| NCT01626456 | A Long-term Safety Study of ALKS 9072 (Also Known as ALKS 9070) | COMPLETED | PHASE3 | 2012-06 | 2015-04 | 2015-04 |
| NCT01500200 | A Study to Evaluate ALKS 5461 in Subjects With Major Depressive Disorder (MDD) | COMPLETED | PHASE2 | 2011-12 | 2013-03 | 2013-03 |
| NCT01469039 | A Study to Evaluate the Efficacy and Safety of ALKS 9072 (Also Known as Aripiprazole Lauroxil, ALKS 9070, or ARISTADA) in Subjects With Schizophrenia | COMPLETED | PHASE3 | 2011-12 | 2014-03 | 2014-01 |
| NCT01493726 | A Study of ALKS 9072 in Subjects With Chronic Stable Schizophrenia | COMPLETED | PHASE1 | 2011-12 | 2013-06 | 2013-06 |
| NCT01436032 | Efficacy, Safety and Tolerability Study of N1539 in Subjects After Abdominal Laparoscopic Surgery | TERMINATED | PHASE3 | 2011-10 | 2012-03 | 2012-03 |
| NCT01418092 | ALK37-007: Evaluation of Safety and Efficacy of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) | COMPLETED | PHASE2 | 2011-09 | 2012-06 | 2012-06 |
| NCT01382797 | ALK37-005: A Study of ALKS 37 (RDC-1036) in Adults With Opioid-induced Constipation (OIC) | COMPLETED | PHASE2 | 2011-08 | 2012-04 | 2012-04 |
| NCT01366001 | ALK33BUP-101: Safety and Pharmacodynamic Effects of ALKS 33-BUP Administered Alone and When Co-administered With Cocaine | COMPLETED | PHASE1 | 2011-08 | 2012-02 | 2012-02 |
| NCT01381107 | ALK33BUP-201: Safety and Tolerability Study of ALKS 33-BUP (ALKS 5461) Administration in Subjects With MDD | COMPLETED | PHASE1, PHASE2 | 2011-05 | 2011-07 | 2011-07 |
| NCT01453374 | A Study of VIVITROL in the Prevention of Re-arrest and Re-incarceration | COMPLETED | PHASE4 | 2011-01 | 2014-05 | 2014-05 |
| NCT01098435 | ALK33-101: A Study of RDC-0313 (ALKS 33) in Adults With Binge Eating Disorder | COMPLETED | PHASE2 | 2010-05 | 2011-06 | 2011-05 |
| NCT01100151 | ALK37-003: A Study of RDC-1036 (ALKS 37) in Adults With Opioid-induced Constipation (OIC) | COMPLETED | PHASE2 | 2010-04 | 2010-12 | 2010-12 |
| NCT01084161 | Study to Evaluate the Efficacy, Safety and Tolerability of N1539 | COMPLETED | PHASE2 | 2010-03 | 2011-01 | 2011-01 |
| NCT00981617 | ALK33-005: A Study of ALKS33 (RDC-0313) in Adults With Alcohol Dependence | COMPLETED | PHASE2 | 2009-10 | 2010-08 | 2010-08 |
| NCT00945763 | Single Dose Study of N1539 in the Treatment of Pain Secondary to Dental Impaction Surgery | COMPLETED | PHASE2 | 2009-07 | 2009-11 | 2009-11 |
| NCT00834080 | ALK21-021: A Safety Study of MedisorbĀ® Naltrexone (VIVITROLĀ®) Administered to Health Care Professionals | COMPLETED | PHASE3 | 2009-03 | 2012-05 | 2012-05 |
| NCT00801684 | ALK27-001: A Study of Trospium Inhalation Powder (TrIP)Administered to Subjects With COPD | COMPLETED | PHASE2 | 2009-02 | 2009-07 | 2009-04 |
| NCT00800319 | ALK33-001: A Study of RDC-0313 Administered to Healthy Adults | COMPLETED | PHASE1 | 2008-12 | 2009-06 | 2009-02 |
| NCT00802035 | ALK29-002: A Study of Baclofen Formulations in Healthy Adults | COMPLETED | PHASE1 | 2008-11 | 2009-02 | 2008-12 |
| NCT00678418 | ALK21-013: Efficacy and Safety of MedisorbĀ® Naltrexone (VIVITROLĀ®) in Adults With Opioid Dependence | COMPLETED | PHASE3 | 2008-06 | 2010-11 | 2009-10 |
| NCT00511836 | ALK21-018: Effects of MedisorbĀ® Naltrexone (VIVITROLĀ®) on Alcohol Craving in Treatment-seeking, Alcohol-dependent Adults | COMPLETED | PHASE4 | 2007-07 | 2009-10 | 2009-06 |
| NCT00501631 | ALK21-014: Efficacy and Safety of MedisorbĀ® Naltrexone (VIVITROLĀ®) After Enforced Abstinence | COMPLETED | PHASE3 | 2007-07 | 2011-03 | 2011-01 |
| NCT00156936 | ALK21-006EXT: Long-term Safety of MedisorbĀ® Naltrexone (VIVITROLĀ®) in Alcohol- or Opioid-dependent Adults (Extension of Study ALK21-006 [NCT01218997]) | TERMINATED | PHASE3 | 2004-08 | 2007-01 | 2007-01 |
| NCT00156923 | ALK21-010: Long-term Safety of MedisorbĀ® Naltrexone (VIVITROLĀ®) in Alcohol-dependent Adults | COMPLETED | PHASE3 | 2003-10 | 2007-01 | 2007-01 |
| NCT01218997 | ALK21-006: Long-Term Study of MedisorbĀ® Naltrexone (VIVITROLĀ®) | COMPLETED | PHASE3 | 2003-08 | 2005-03 | 2005-03 |
| NCT01218971 | ALK21-003EXT: An Extension of Study ALK21-003 (NCT01218958) to Test the Long-term Safety of MedisorbĀ® Naltrexone (VIVITROLĀ®) | COMPLETED | PHASE3 | 2002-08 | 2004-09 | 2004-09 |
| NCT01218984 | ALK21-004: Single-dose Opiate Challenge of MedisorbĀ® Naltrexone (VIVITROLĀ®) in Adults Who Use Opioids | COMPLETED | PHASE2 | 2002-03 | 2003-05 | 2003-05 |
| NCT01218958 | ALK21-003: Study of MedisorbĀ® Naltrexone (VIVITROLĀ®) in Alcohol-Dependent Adults | COMPLETED | PHASE3 | 2002-02 | 2003-09 | 2003-09 |
| NCT00002316 | The Safety and Effectiveness of RMP-7 Plus Amphotericin B in Patients With HIV and Cryptococcal Meningitis | COMPLETED | PHASE1 | | | |